(ZVIA) Zevia Pbc - Overview
Stock: Soda, Energy, Tea
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.6% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -72.43 |
| Character TTM | |
|---|---|
| Beta | 1.077 |
| Beta Downside | 0.716 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.91% |
| CAGR/Max DD | -0.34 |
Description: ZVIA Zevia Pbc January 02, 2026
Zevia PBC (NYSE: ZVIA) is a publicly-listed company that formulates, markets and distributes zero-sugar carbonated soft drinks, energy drinks and organic teas across the United States and Canada. Founded in 2007 and headquartered in Encino, California, its product portfolio is sold through a broad retail mix that includes grocery chains, convenience stores, warehouse clubs, natural-product outlets and e-commerce platforms.
Key operational metrics (FY 2023) show revenue of roughly $140 million, a year-over-year increase of about 12 % driven primarily by expansion in the natural-products channel, while the company posted a net loss of $22 million and maintained a cash balance of $45 million, giving it roughly 12 months of runway at current burn rates. The zero-sugar segment has outperformed the broader packaged-foods industry, which is experiencing a 4-5 % CAGR as consumers shift away from sugar-sweetened beverages and regulators impose sugar taxes in several jurisdictions.
Sector-level drivers that materially affect Zevia include (1) the ongoing health-conscious consumer trend, which has lifted the market share of “better-for-you” drinks to an estimated 8 % of total U.S. carbonated beverage volume, (2) rising input costs for natural sweeteners (e.g., stevia) that can compress margins if not passed through to customers, and (3) the competitive pressure from both legacy soda makers launching low-calorie lines and emerging niche brands expanding their distribution footprints.
For a deeper, data-rich assessment of Zevia’s valuation and risk profile, you may find the ValueRay research platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -14.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA -2.61 > 1.0 |
| NWC/Revenue: 18.75% < 20% (prev 27.95%; Δ -9.19% < -1%) |
| CFO/TA -0.10 > 3% & CFO -6.19m > Net Income -14.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.3m) vs 12m ago 13.17% < -2% |
| Gross Margin: 48.36% > 18% (prev 0.44%; Δ 4792 % > 0.5%) |
| Asset Turnover: 245.1% > 50% (prev 210.5%; Δ 34.61% > 0%) |
| Interest Coverage Ratio: -4.02 > 6 (EBITDA TTM -12.3m / Interest Expense TTM 3.31m) |
Altman Z'' -10.70
| A: 0.51 (Total Current Assets 54.5m - Total Current Liabilities 24.0m) / Total Assets 60.0m |
| B: -2.17 (Retained Earnings -130.0m / Total Assets 60.0m) |
| C: -0.20 (EBIT TTM -13.3m / Avg Total Assets 66.4m) |
| D: -5.36 (Book Value of Equity -129.9m / Total Liabilities 24.2m) |
| Altman-Z'' Score: -10.70 = D |
Beneish M -2.89
| DSRI: 1.19 (Receivables 12.6m/10.0m, Revenue 162.8m/153.4m) |
| GMI: 0.92 (GM 48.36% / 44.27%) |
| AQI: 1.26 (AQ_t 0.07 / AQ_t-1 0.05) |
| SGI: 1.06 (Revenue 162.8m / 153.4m) |
| TATA: -0.14 (NI -14.4m - CFO -6.19m) / TA 60.0m) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of ZVIA shares?
Over the past week, the price has changed by -8.29%, over one month by -11.23%, over three months by -36.40% and over the past year by -52.16%.
Is ZVIA a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZVIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.8 | 187.3% |
| Analysts Target Price | 4.8 | 187.3% |
| ValueRay Target Price | 1.4 | -16.9% |
ZVIA Fundamental Data Overview February 03, 2026
P/B = 2.3931
Revenue TTM = 162.8m USD
EBIT TTM = -13.3m USD
EBITDA TTM = -12.3m USD
Long Term Debt = 830.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 643.0k USD (from shortTermDebt, last quarter)
Debt = 830.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -25.2m USD (from netDebt column, last quarter)
Enterprise Value = 99.3m USD (124.5m + Debt 830.0k - CCE 26.0m)
Interest Coverage Ratio = -4.02 (Ebit TTM -13.3m / Interest Expense TTM 3.31m)
EV/FCF = -15.38x (Enterprise Value 99.3m / FCF TTM -6.46m)
FCF Yield = -6.50% (FCF TTM -6.46m / Enterprise Value 99.3m)
FCF Margin = -3.97% (FCF TTM -6.46m / Revenue TTM 162.8m)
Net Margin = -8.83% (Net Income TTM -14.4m / Revenue TTM 162.8m)
Gross Margin = 48.36% ((Revenue TTM 162.8m - Cost of Revenue TTM 84.1m) / Revenue TTM)
Gross Margin QoQ = 45.58% (prev 48.72%)
Tobins Q-Ratio = 1.66 (Enterprise Value 99.3m / Total Assets 60.0m)
Interest Expense / Debt = 139.9% (Interest Expense 1.16m / Debt 830.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -10.5m (EBIT -13.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.27 (Total Current Assets 54.5m / Total Current Liabilities 24.0m)
Debt / Equity = 0.02 (Debt 830.0k / totalStockholderEquity, last quarter 51.2m)
Debt / EBITDA = 2.05 (negative EBITDA) (Net Debt -25.2m / EBITDA -12.3m)
Debt / FCF = 3.90 (negative FCF - burning cash) (Net Debt -25.2m / FCF TTM -6.46m)
Total Stockholder Equity = 55.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.63% (Net Income -14.4m / Total Assets 60.0m)
RoE = -25.79% (Net Income TTM -14.4m / Total Stockholder Equity 55.7m)
RoCE = -23.51% (EBIT -13.3m / Capital Employed (Equity 55.7m + L.T.Debt 830.0k))
RoIC = -18.85% (negative operating profit) (NOPAT -10.5m / Invested Capital 55.7m)
WACC = 9.81% (E(124.5m)/V(125.4m) * Re(9.88%) + (debt cost/tax rate unavailable))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.55%
Fair Price DCF = unknown (Cash Flow -6.46m)
EPS Correlation: 59.04 | EPS CAGR: 5.21% | SUE: 1.41 | # QB: 3
Revenue Correlation: 10.13 | Revenue CAGR: 4.87% | SUE: 0.66 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.002 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.07 | Chg30d=+0.002 | Revisions Net=+1 | Growth EPS=+50.0% | Growth Revenue=+6.5%